MTM(SH:688029)2021-04-19 16:00Financial Performance - Operating revenue for Q1 2021 reached CNY 393,518,815.47, a year-on-year increase of 59.47%[5] - Net profit attributable to shareholders was CNY 66,848,213.45, up 41.10% from the same period last year[5] - Domestic sales revenue for Q1 2021 was CNY 227,000,000, a significant increase of 91.89% year-on-year[6] - International sales revenue for Q1 2021 reached CNY 166,000,000, representing a year-on-year growth of 29.64%[6] - Basic earnings per share rose to CNY 0.5013, an increase of 41.09% year-on-year[6] - The company reported a total comprehensive income of ¥68,157,770.33 for Q1 2021, compared to ¥45,420,064.65 in Q1 2020, reflecting a growth of 50.1%[43] - The company reported a net profit of ¥632,487,267.84, up from ¥565,639,054.39, which is an increase of approximately 11.8% year-over-year[32] Cash Flow - The company reported a net cash flow from operating activities of CNY 57,223,313.91, compared to a negative cash flow of CNY -21,406,401.02 in the same period last year[5] - Cash inflows from operating activities amounted to ¥400,881,817.60 in Q1 2021, compared to ¥289,522,667.19 in Q1 2020, representing a year-over-year increase of about 38.5%[47] - The net cash flow from investment activities was negative at -¥98,324,547.57, compared to a positive net cash flow of ¥77,467,608.40 in Q1 2020[49] - Cash and cash equivalents at the end of Q1 2021 totaled ¥603,316,173.81, down from ¥701,074,206.06 at the end of Q1 2020, reflecting a decrease of about 14%[49] Assets and Liabilities - Total assets increased by 3.72% to CNY 3,220,607,551.41 compared to the end of the previous year[5] - The company's total prepayments increased by 60.81% to RMB 30,341,185.48 as of March 31, 2021, compared to RMB 18,867,634.66 at the end of 2020[11] - The company's intangible assets rose by 55.32% to RMB 25,508,328.31, primarily due to the implementation of SAP software[11] - Total liabilities reached ¥466,348,877.29, compared to ¥441,592,548.79, marking an increase of around 5.6%[31] - Current liabilities rose to ¥444,321,617.86, up from ¥421,146,827.58, reflecting a growth of approximately 5.0%[30] Research and Development - R&D expenditure accounted for 7.00% of operating revenue, a slight decrease of 0.29 percentage points compared to the previous year[6] - Research and development expenses increased by 53.11% to RMB 27,561,258.83 in Q1 2021, reflecting the company's focus on new product development[15] - Research and development expenses for Q1 2021 amounted to ¥27,561,258.83, an increase of 53.4% from ¥18,001,211.42 in Q1 2020[40] Market Expansion and Product Development - The company is expanding its product line with new registrations, including the Ensure(TM) Single-Use Coagulation Forceps and various stents in multiple markets[23] - The company is actively pursuing market expansion in regions such as Peru, Argentina, and Malaysia with new product registrations[24] - The company received multiple product registration certificates in various countries, including Canada, Peru, and the United States, for new medical devices during the reporting period[21] - The company is focused on enhancing its product portfolio through continuous innovation and regulatory compliance in international markets[26] Tax and Expenses - The company's tax expenses increased by 68.17% to RMB 14,861,974.79 in Q1 2021, driven by higher sales revenue and profits[16] - Operating costs for Q1 2021 were ¥318,764,464.08, up 59.9% from ¥199,574,798.19 in the same period last year[38]